Canbex Therapeutics Ltd 
Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity.
Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS. Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.
Canbex closed a $3.2m financing round led by Merck Serono Ventures in April 2013, and its lead anti-spasticity compound, VSN16R, is set to enter Phase I safety testing. In studies to date, VSN16R shows substantially improved tolerability compared to other compounds, and is as effective against spasticity as any other agent known.
Supported by its leading London-based scientific and clinical team, Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity.
To find out more, please meet us at the event or contact us using the details below
Canbex Therapeutics Ltd
London BioScience Innovation Centre
2 Royal College Street
London
NW1 0NH
Tel: +44 (0)207 554 5872
Email: enquiries@canbex.co.uk
